Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

Trial Profile

CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenicriviroc (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms CENTAUR
  • Sponsors Tobira Therapeutics
  • Most Recent Events

    • 18 Jul 2019 According to European Clinical Trials Registry record, Canada, Israel, Moldova and Romania were in planned location.
    • 11 Jun 2019 Results evaluating efficacy, cytokines and metabolic parameters of Cenicriviroc were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
    • 11 Jun 2019 Results assessing tolerability of cenicriviroc in adults with NASH and fibrosis, presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top